{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:59Z","timestamp":1790957579204,"version":"4.1.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the effect of calcium channel blockers (CCBs) on tacrolimus blood concentrations in renal transplant recipients with different <jats:italic>CYP3A5<\/jats:italic> genotypes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study included renal transplant recipients receiving tacrolimus-based immunosuppressive therapy with or without CCBs in combination. Patients were divided into combination and control groups based on whether or not they were combined with CCBs, and then further analyzed according to the type of CCBs (nifedipine\/amlodipine\/felodipine). Propensity score matching was conducted for the combination and the control groups using SPSS 22.0 software to reduce the impact of confounding factors. The effect of different CCBs on tacrolimus blood concentrations was evaluated, and subgroup analysis was performed according to the patients\u2019 <jats:italic>CYP3A5<\/jats:italic> genotypes to explore the role of <jats:italic>CYP3A5<\/jats:italic> genotypes in drug-drug interactions between tacrolimus and CCBs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 164 patients combined with CCBs were included in the combination groups. After propensity score matching, 83 patients with nifedipine were matched 1:1 with the control group, 63 patients with felodipine were matched 1:2 with 126 controls, and 18 patients with amlodipine were matched 1:3 with 54 controls. Compared with the controls, the three CCBs increased the dose-adjusted trough concentration (C<jats:sub>0<\/jats:sub>\/D) levels of tacrolimus by 41.61%\u201345.57% (<jats:italic>P<\/jats:italic> &amp;lt; 0.001). For both <jats:italic>CYP3A5<\/jats:italic> expressers (<jats:italic>CYP3A5*1*1<\/jats:italic> or <jats:italic>CYP3A5*1*3<\/jats:italic>) and non-expressers (<jats:italic>CYP3A5*3*3<\/jats:italic>), there were significant differences in tacrolimus C<jats:sub>0<\/jats:sub>\/D between patients using felodipine\/nifedipine and those without CCBs (<jats:italic>P<\/jats:italic> &amp;lt; 0.001). However, among <jats:italic>CYP3A5<\/jats:italic> non-expressers, C<jats:sub>0<\/jats:sub>\/D values of tacrolimus were significantly higher in patients combined with amlodipine compared to the controls (<jats:italic>P<\/jats:italic> = 0.001), while for <jats:italic>CYP3A5<\/jats:italic> expressers, the difference in tacrolimus C<jats:sub>0<\/jats:sub>\/D values between patients with amlodipine and without was not statistically significant (<jats:italic>P<\/jats:italic> = 0.065).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CCBs (felodipine\/nifedipine\/amlodipine) can affect tacrolimus blood concentration levels by inhibiting its metabolism. The <jats:italic>CYP3A5<\/jats:italic> genotype may play a role in the drug interaction between tacrolimus and amlodipine. Therefore, genetic testing for tacrolimus and therapeutic drug monitoring are needed when renal transplant recipients are concurrently using CCBs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1458838","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T05:08:19Z","timestamp":1724908099000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Interaction between tacrolimus and calcium channel blockers based on CYP3A5 genotype in Chinese renal transplant recipients"],"prefix":"10.3389","volume":"15","author":[{"given":"Huiying","family":"Zong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yundi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penglin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/FPC.0b013e328364db84","article-title":"PharmGKB summary: cyclosporine and tacrolimus pathways","volume":"23","author":"Barbarino","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"B2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) Guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/00007890-200201150-00033","article-title":"Effect of felodipine on tacrolimus pharmacokinetics in a renal transplant recipient","volume":"73","author":"Butani","year":"2002","journal-title":"Transplantation"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2147\/PGPM.S337947","article-title":"Genetic polymorphisms affecting tacrolimus metabolism and the relationship to post-transplant outcomes in kidney transplant recipients","volume":"14","author":"Cheng","year":"2021","journal-title":"Pharmgenomics Pers. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.transproceed.2019.04.019","article-title":"Impact of CYP3A5 genetic polymorphism on intrapatient variability of tacrolimus exposure in Chinese kidney transplant recipients","volume":"51","author":"Cheung","year":"2019","journal-title":"Transpl. Proc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.5414\/cnp57409","article-title":"Hypertension in renal transplantation: donor and recipient risk factors","volume":"57","author":"Ducloux","year":"2002","journal-title":"Clin. Nephrol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2217\/pgs-2016-0146","article-title":"Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes","volume":"18","author":"Flahault","year":"2017","journal-title":"Pharmacogenomics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e00892","DOI":"10.1002\/prp2.892","article-title":"Real clinical impact of drug-drug interactions of immunosuppressants in transplant patients","volume":"9","author":"Gago-S\u00e1nchez","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/ndt\/gfx283","article-title":"Optimizing hypertension management in renal transplantation","volume":"32","author":"Halimi","year":"2017","journal-title":"Nephrology, Dialysis, Transplantation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2165\/00003495-198700343-00010","article-title":"Metabolism of [14C] felodipine, a new vasodilating drug, in healthy volunteers","volume":"34","author":"Hoffmann","year":"1987","journal-title":"Drugs"},{"key":"B11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/00000658-199909000-00016","article-title":"What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients","volume":"230","author":"Jain","year":"1999","journal-title":"Ann. Surg."},{"key":"B12","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/CNQ.0000000000000117","article-title":"Immunosuppression in solid-organ transplantation: essentials and practical tips","volume":"39","author":"Jasiak","year":"2016","journal-title":"Crit. Care Nurs. Q."},{"key":"B13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s002280050706","article-title":"Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions","volume":"55","author":"Katoh","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am. J. Transpl."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","article-title":"Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review","volume":"59","author":"Kirubakaran","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41397-019-0141-x","article-title":"Kidney podocyte-associated gene polymorphisms affect tacrolimus concentration in pediatric patients with refractory nephrotic syndrome","volume":"20","author":"Mo","year":"2020","journal-title":"Pharmacogenomics J."},{"key":"B18","first-page":"197","article-title":"Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level","volume":"13","author":"Nair","year":"2015","journal-title":"Exp. Clin. Transpl."},{"key":"B19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2217\/pgs.15.42","article-title":"Multigene predictors of tacrolimus exposure in kidney transplant recipients","volume":"16","author":"Pulk","year":"2015","journal-title":"Pharmacogenomics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2174\/1389200217666151210125831","article-title":"Influence of CYP3A5 polymorphism on the pharmacokinetics of psychiatric drugs","volume":"17","author":"Ragia","year":"2016","journal-title":"Curr. Drug Metab."},{"key":"B21","doi-asserted-by":"publisher","first-page":"813","DOI":"10.2298\/vsp140905005r","article-title":"Tacrolimus concentration\/dose ratio as a therapeutic drug monitoring strategy: the influence of gender and comedication","volume":"72","author":"Ran\u010di\u0107","year":"2015","journal-title":"Vojnosanit. Pregl."},{"key":"B22","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1177\/106002809703100508","article-title":"Nifedipine interaction with tacrolimus in liver transplant recipients","volume":"31","author":"Seifeldin","year":"1997","journal-title":"Ann. Pharmacother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ccc.2018.08.011","article-title":"Complications of solid organ transplantation: cardiovascular, neurologic, renal, and gastrointestinal","volume":"35","author":"Sen","year":"2019","journal-title":"Crit. Care Clin."},{"key":"B24","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/MOT.0000000000000722","article-title":"Future developments in kidney transplantation","volume":"25","author":"Viklicky","year":"2020","journal-title":"Curr. Opin. Organ Transpl."},{"key":"B25","doi-asserted-by":"publisher","first-page":"692922","DOI":"10.3389\/fphar.2021.692922","article-title":"CYP3A5 genotype-dependent drug-drug interaction between tacrolimus and nifedipine in Chinese renal transplant patients","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ajh.2008.305","article-title":"Inhibitory effect of antihypertensive drugs on calcineurin in cardiomyocytes","volume":"22","author":"Zhang","year":"2009","journal-title":"Am. J. Hypertens."},{"key":"B27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2133\/dmpk.dmpk-12-rg-148","article-title":"Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine","volume":"28","author":"Zuo","year":"2013","journal-title":"Drug Metab. Pharmacokinet."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1458838\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T05:08:22Z","timestamp":1724908102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1458838\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":27,"alternative-id":["10.3389\/fphar.2024.1458838"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1458838","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"article-number":"1458838"}}